Figure 1From: Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study) Schematic description of the NEOPAC trial. Patients are randomized to either receive the standard treatment (surgery+adjuvant chemotherapy) or neoadjuvant chemotherapy followed by the standard treatment.Back to article page